Navigate Fool.com
Will EPZM beat
the market?

Epizyme (NASDAQ: EPZM)

Community Rating: 3 Stars: Appealing

33.21 2.80 (9.21%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $30.84
Previous Close $30.41
Daily Range $30.52 - $33.33
52-Week Range $18.10 - $42.71
Market Cap $1.1B
P/E Ratio 7.94
Dividend (Yield) $0.00 (0.0%)
Volume 301,850
Average Daily Volume 272,791
Current FY EPS -$1.72

How do you think EPZM
will perform against the market?

Top EPZM Bull/Bear Pitches


zzlangerhans (< 20)
Submitted April 3, 2014

Biopharmas addressing hematologic malignancies have been pretty good bets over the last few years (see Pharmacyclics, Seattle Genetics), so traders could be excused for rocking Epizyme's IPO and makin … More

0 Replies Reply Report this Post

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

Why Epizyme Inc. Shares Rocketed Higher

Epizyme shares soar after the company reaches another creative milestone with partner GlaxoSmithKline.

What You Ought To Know About Celgene's Deal-Making Magic

Celgene's investment team has made a string of savvy investments in early stage biotech companies.

Stocks: Insiders Buy at Epizyme and Intergrated Device Technology

Plus, purchases at Genocea Biosciences and Gladstone Investment and a sale at Epizyme.

Biotech Boom Set to Smash IPO Record for Two-Week Period

Epizyme Heads Back to Wall Street, Plans $140M Raise

Was Celgene Corporation's Preview Really $2 Billion Worth of Disappointment?

Celgene disappointed investors with a Q4 earnings miss and lower-than-expected 2014 earnings projections. But was the news really that bad?

Celgene's Bet on Epizyme Pays Off

Celgene and Epizyme got a big boost this week when Epizyme's EPZ-5676 met an important milestone.

This Week in Biotech: Putting On a Clinic

In part one of This Week in Biotech we're looking at four encouraging clinical trials, including a company that gained 545%, as well as an announced collaboration and a buyout.

3 Humongous Health-Care Stocks This Week

Intercept Pharmaceuticals, Neurocrine Biosciences, and Epizyme achieve stunning gains in a great week for health-care investors.

Why Neurocrine Biosciences, Epizyme, and Plug Power Are Today's 3 Best Stocks

The S&P 500 delivers its first gain of the year while Neurocrine Biosciences, Epizyme, and Plug Power all rocket higher by at least 39%!

See More EPZM News...



Epizyme (EPZM) Description

Epizyme Inc is a clinical stage biopharmaceutical company that discovers develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. Website: http://www.epizyme.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks